Kh D Mongush

Republican Hospital No. 1, Kyzyl, Russia.

3 publications 2011 – 2025 ORCID
RussiaRegistriesIschemic StrokeFibrinolytic AgentsCerebral Hemorrhage

What does Kh D Mongush research?

Kh D Mongush studies the impact of Revelise (alteplase) as a treatment for ischemic stroke, a type of stroke caused by blocked blood flow to the brain. Their research investigates how well this medication works in everyday clinical settings, particularly in older patients and those with other existing health issues. By analyzing a large group of patients, they explore how treatment can enhance recovery and reduce disabilities associated with strokes.

Key findings

  • In the two-year follow-up of 2,202 patients, 49.9% had good outcomes at discharge.
  • At 90 days post-treatment, this percentage increased to 66.4%, indicating significant improvement over time.
  • The study highlighted that Revelise effectively reduces stroke-related disabilities, even among older patients.

Frequently asked questions

Does Dr. Mongush study ischemic stroke?
Yes, Dr. Mongush specifically focuses on ischemic stroke and the effectiveness of related treatments.
What treatments has Dr. Mongush researched?
Dr. Mongush has researched the use of Revelise (alteplase), a medication for treating ischemic stroke.
Is Dr. Mongush's work relevant to older patients?
Yes, their research examines how Revelise benefits older patients and those with additional health conditions.

Publications in plain English

[Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +92 more

Plain English
This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options. Who this helps: Patients with acute ischemic stroke and their healthcare providers.

PubMed

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Epidemiology of epilepsy in Republic of Tyva].

2011

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Doronin BM, Mongush KhD

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.